NCT06910072Enrolling by invitationPhase 2/3
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 28 Feb 2025
- Start date
- 21 Jul 2025
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT06910072
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 32
- From 21 Jul 2025 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The presence of any autoimmune disease that still requires treatment or a history of prior autoimmune disease
Other illness
- Bilateral breast cancer
- There is a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
- A history of invasive or metastatic breast cancer
- Any malignancy diagnosed within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma
- There is an immune deficiency disease
Who the study is looking for
- Triple-negative breast cancer
- The diameter of the primary tumor must be greater than 2cm, and the clinical stage should be II-III
- There is sufficient primary organ function
- The ECOG (PS) score is 0 or 1
- Expected survival ≥ 6 months
- The serum pregnancy test was negative. Use highly effective methods of contraception during the study period and for 180 days after the last dose of the study drug, and do not breastfeed
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.